Pharma firm Strides Arcolab today said its subsidiary Onco Therapies Ltd has received final approval from the US health regulator for its generic version of Oxaliplatin injection used for treating cancer. The nod from the US Food and Drug Administration is for Oxaliplatin injection in strengths of 50mg/10ml and 100mg/20ml, the company said in a statement. “The company had in November 2011 received tentative approval from USFDA based on a Para III filing. This approval was later converted to a Para IV filing based on which USFDA has now granted final approval,” it added.
